All Stories

  1. Data from A Dendritic Cell–Like Transition of T Cells Is Associated with Spontaneous Remission of Adult T-Cell Leukemia–Lymphoma
  2. Supplementary Figure 1 from A Dendritic Cell–Like Transition of T Cells Is Associated with Spontaneous Remission of Adult T-Cell Leukemia–Lymphoma
  3. Supplementary Figure 2 from A Dendritic Cell–Like Transition of T Cells Is Associated with Spontaneous Remission of Adult T-Cell Leukemia–Lymphoma
  4. Supplementary Figure 3 from A Dendritic Cell–Like Transition of T Cells Is Associated with Spontaneous Remission of Adult T-Cell Leukemia–Lymphoma
  5. Supplementary Figure 4 from A Dendritic Cell–Like Transition of T Cells Is Associated with Spontaneous Remission of Adult T-Cell Leukemia–Lymphoma
  6. Supplementary Figure 5 from A Dendritic Cell–Like Transition of T Cells Is Associated with Spontaneous Remission of Adult T-Cell Leukemia–Lymphoma
  7. Supplementary Figure 6 from A Dendritic Cell–Like Transition of T Cells Is Associated with Spontaneous Remission of Adult T-Cell Leukemia–Lymphoma
  8. Supplementary Figure 7 from A Dendritic Cell–Like Transition of T Cells Is Associated with Spontaneous Remission of Adult T-Cell Leukemia–Lymphoma
  9. Supplementary Table S1 from A Dendritic Cell–Like Transition of T Cells Is Associated with Spontaneous Remission of Adult T-Cell Leukemia–Lymphoma
  10. Supplementary Table S2 from A Dendritic Cell–Like Transition of T Cells Is Associated with Spontaneous Remission of Adult T-Cell Leukemia–Lymphoma
  11. Supplementary Table S3 from A Dendritic Cell–Like Transition of T Cells Is Associated with Spontaneous Remission of Adult T-Cell Leukemia–Lymphoma
  12. Supplementary Table S4 from A Dendritic Cell–Like Transition of T Cells Is Associated with Spontaneous Remission of Adult T-Cell Leukemia–Lymphoma
  13. Supplementary Table S5 from A Dendritic Cell–Like Transition of T Cells Is Associated with Spontaneous Remission of Adult T-Cell Leukemia–Lymphoma
  14. JunB–HBZ nuclear translocation by TGF-β is a key driver in HTLV-1-mediated leukemogenesis
  15. Evolution of primate T-cell leukemia virus type 1 accessory genes and functional divergence of its antisense proteins
  16. A Dendritic Cell–Like Transition of T Cells Is Associated with Spontaneous Remission of Adult T-Cell Leukemia–Lymphoma
  17. JunB-HBZ nuclear translocation by TGF-β is a key driver in HTLV-1–mediated leukemogenesis
  18. Vulnerability to APOBEC3G linked to the pathogenicity of deltaretroviruses
  19. Diagnosis and clinical management of Exophiala dermatitidis pneumonia in a patient with anorexia nervosa: A case report
  20. Phospholipid metabolic adaptation promotes survival of IDH2 mutant acute myeloid leukemia cells
  21. Possible Association of Mutations in the MEFV Gene with the Intestinal Phenotype of Behçet’s Disease and Refractoriness to Treatment
  22. Targeting vulnerabilities of adult T-cell leukemia
  23. A novel PDK1 inhibitor, JX06, inhibits glycolysis and induces apoptosis in multiple myeloma cells
  24. The HTLV-1 proviral status is a potential prognostic biomarker for adult T-cell leukemia-lymphoma treated with allogeneic stem cell transplantation
  25. Human retroviral antisense mRNAs are retained in the nuclei of infected cells for viral persistence
  26. Adult T‐cell leukemia‐lymphoma as a viral disease: Subtypes based on viral aspects
  27. The noncanonical role of EZH2 in cancer
  28. In vivo dynamics and adaptation of HTLV-1-infected clones under different clinical conditions
  29. Systematic clustering algorithm for chromatin accessibility data and its application to hematopoietic cells
  30. HTLV-1 induces T cell malignancy and inflammation by viral antisense factor-mediated modulation of the cytokine signaling
  31. HTLV-1 bZIP factor: the key viral gene for pathogenesis
  32. Clinical potential of dual-energy cardiac CT in cardiac amyloidosis
  33. The history and future of HTLV-1 research
  34. CADM1 is a diagnostic marker in early-stage mycosis fungoides: Multicenter study of 58 cases
  35. Evaluating the origin and virulence of a Helicobacter pylori cagA-positive strain isolated from a non-human primate
  36. Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation
  37. Pancytopenia and Myelodysplastic Changes in Aceruloplasminemia: A Case with a Novel Pathogenic Variant in the Ceruloplasmin Gene
  38. HTLV-1 Alters T Cells for Viral Persistence and Transmission
  39. Mogamulizumab (Anti-CCR4) in HTLV-1–Associated Myelopathy
  40. Sporadic on/off switching of HTLV-1 Tax expression is crucial to maintain the whole population of virus-induced leukemic cells
  41. Isolated Pancreatic Myeloid Sarcoma Associated with t(8;21)/RUNX1-RUNX1T1 Rearrangement
  42. Oncogenic spiral by infectious pathogens: Cooperation of multiple factors in cancer development
  43. Circadian clock regulates hepatic polyploidy by modulating Mkp1-Erk1/2 signaling pathway
  44. Human T-cell leukemia virus type 1 infects multiple lineage hematopoietic cells in vivo
  45. Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma
  46. HTLV-1 bZIP factor suppresses TDP1 expression through inhibition of NRF-1 in adult T-cell leukemia
  47. Human T-cell leukaemia virus type 1: parasitism and pathogenesis
  48. HTLV-1 bZIP Factor Enhances T-Cell Proliferation by Impeding the Suppressive Signaling of Co-inhibitory Receptors
  49. Reducing the global burden of HTLV-1 infection: An agenda for research and action
  50. Screening transplant donors for HTLV-1 and -2
  51. An IL‐27/Stat3 axis induces expression of programmed cell death 1 ligands ( PD ‐L1/2) on infiltrating macrophages in lymphoma
  52. Enhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors
  53. HTLV-1 Viral Factor HBZ Induces CCR4 to Promote T-cell Migration and Proliferation
  54. TIM-3 expression in lymphoma cells predicts chemoresistance in patients with adult T-cell leukemia/lymphoma
  55. Impact of the SCF signaling pathway on leukemia stem cell-mediated ATL initiation and progression in an HBZ transgenic mouse model
  56. Enhancement of anti-STLV-1/HTLV-1 immune responses through multimodal effects of anti-CCR4 antibody
  57. Multifaceted functions and roles of HBZ in HTLV-1 pathogenesis
  58. Gpr176 is a Gz-linked orphan G-protein-coupled receptor that sets the pace of circadian behaviour
  59. HTLV-1 bZIP factor protein targets the Rb/E2F-1 pathway to promote proliferation and apoptosis of primary CD4+ T cells
  60. HTLV-1 bZIP Factor Impairs Anti-viral Immunity by Inducing Co-inhibitory Molecule, T Cell Immunoglobulin and ITIM Domain (TIGIT)
  61. HTLV-1 subgroups associated with the risk of HAM/TSP are related to viral and host gene expression in peripheral blood mononuclear cells, independent of the transactivation functions of the viral factors
  62. Correction: Interferon-γ Promotes Inflammation and Development of T-Cell Lymphoma in HTLV-1 bZIP Factor Transgenic Mice
  63. Integrated molecular analysis of adult T cell leukemia/lymphoma
  64. Impact of HIV-1 infection pathways on susceptibility to antiviral drugs and on virus spread
  65. HTLV-1 bZIP Factor RNA and Protein Impart Distinct Functions on T-cell Proliferation and Survival
  66. Experimental evaluation of the zoonotic infection potency of simian retrovirus type 4 using humanized mouse model
  67. Interferon-γ Promotes Inflammation and Development of T-Cell Lymphoma in HTLV-1 bZIP Factor Transgenic Mice
  68. Protective effect of cytotoxic T lymphocytes targeting HTLV-1 bZIP factor
  69. Identification of anti-HIV agents with a novel benzo[4,5]isothiazolo[2,3-a]pyrimidine scaffold
  70. Human T ‐cell leukemia virus type 1 T ax oncoprotein represses the expression of the BCL 11 B tumor suppressor in T ‐cells
  71. TCF1 and LEF1 act as T-cell intrinsic HTLV-1 antagonists by targeting Tax
  72. Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study
  73. Investigations of possible prodrug structures for 2-(2-mercaptophenyl)tetrahydropyrimidines: reductive conversion from anti-HIV agents with pyrimidobenzothiazine and isothiazolopyrimidine scaffolds
  74. Reevaluation of confirmatory tests for human T-cell leukemia virus Type 1 using a luciferase immunoprecipitation system in blood donors
  75. A Critical Role for IL-17RB Signaling in HTLV-1 Tax-Induced NF-κB Activation and T-Cell Transformation
  76. Development of T cell lymphoma in HTLV-1 bZIP factor and Tax double transgenic mice
  77. Human T-cell leukemia virus type 1 and Foxp3 expression: viral strategy in vivo
  78. The role of HTLV-1 clonality, proviral structure, and genomic integration site in adult T-cell leukemia/lymphoma
  79. Conference Highlights of the 16th International Conference on Human Retrovirology: HTLV and Related Retroviruses, 26–30 June 2013, Montreal, Canada
  80. Epstein–Barr Viral Load is Associated to Response in AIDS-Related Lymphomas
  81. Involvement of double-stranded RNA-dependent protein kinase and antisense viral RNA in the constitutive NFκB activation in adult T-cell leukemia/lymphoma cells
  82. Controlling leucine-zipper partner recognition in cells through modification of a–g interactions
  83. HTLV-1 proviral integration sites differ between asymptomatic carriers and patients with HAM/TSP
  84. Human T-Cell Leukemia Virus Type 1: Pathogenesis and Host Immune Response
  85. HIV-1 Vpr Accelerates Viral Replication during Acute Infection by Exploitation of Proliferating CD4+ T Cells In Vivo
  86. HTLV-1 bZIP factor supports proliferation of adult T cell leukemia cells through suppression of C/EBPα signaling
  87. Human T-cell leukemia virus type 1: replication, proliferation and propagation by Tax and HTLV-1 bZIP factor
  88. HTLV-1 bZIP Factor Suppresses Apoptosis by Attenuating the Function of FoxO3a and Altering Its Localization
  89. HTLV-1 bZIP Factor Induces Inflammation through Labile Foxp3 Expression
  90. Structure–activity relationship study of phenylpyrazole derivatives as a novel class of anti-HIV agents
  91. HIV-1 Resistance Mechanism to an Electrostatically Constrained Peptide Fusion Inhibitor That Is Active against T-20-Resistant Strains
  92. Virological and immunological mechanisms in the pathogenesis of human T-cell leukemia virus type 1
  93. Design and synthesis of biotin- or alkyne-conjugated photoaffinity probes for studying the target molecules of PD 404182
  94. Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design
  95. Comprehensive In Vitro Analysis of Simian Retrovirus Type 4 Susceptibility to Antiretroviral Agents
  96. Characterization of simian T-cell leukemia virus type 1 in naturally infected Japanese macaques as a model of HTLV-1 infection
  97. Structure–activity relationship study of pyrimido[1,2-c][1,3]benzothiazin-6-imine derivatives for potent anti-HIV agents
  98. CXCR4 Stimulates Macropinocytosis: Implications for Cellular Uptake of Arginine-Rich Cell-Penetrating Peptides and HIV
  99. HTLV-1 bZIP factor dysregulates the Wnt pathways to support proliferation and migration of adult T-cell leukemia cells
  100. A simple, rapid, and sensitive system for the evaluation of anti-viral drugs in rats
  101. Human T-Cell Leukemia Virus Type 1 (HTLV-1) bZIP Factor Requires Cellular Transcription Factor JunD To Upregulate HTLV-1 Antisense Transcription from the 3' Long Terminal Repeat
  102. HTLV-1 modulates the frequency and phenotype of FoxP3+CD4+T cells in virus-infected individuals
  103. Development and application of fluorescent SDF-1 derivatives
  104. FOXP3+ regulatory and TIA-1+ cytotoxic T lymphocytes in HIV-associated Hodgkin lymphoma
  105. Concise synthesis and anti-HIV activity of pyrimido[1,2-c][1,3]benzothiazin-6-imines and related tricyclic heterocycles
  106. HBZ and its roles in HTLV-1 oncogenesis
  107. The 2011 Retrovirology Prize winner Masao Matsuoka: forward looking and antisense
  108. HTLV-1 bZIP factor impairs cell-mediated immunity by suppressing production of Th1 cytokines
  109. HTLV-2 APH-2 Expression Is Correlated With Proviral Load but APH-2 Does Not Promote Lymphocytosis
  110. Guest editorial: a new era of ATL and HTLV-1 research
  111. Potent Anti-HIV-1 Activity of N-HR-Derived Peptides Including a Deep Pocket-Forming Region without Antagonistic Effects on T-20
  112. Molecular mechanisms of HTLV-1 infection and pathogenesis
  113. HTLV-1 bZIP factor enhances TGF-  signaling through p300 coactivator
  114. Detection of HTLV-1 by means of HBZ gene in situ hybridization in formalin-fixed and paraffin-embedded tissues
  115. A novel animal model of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice
  116. Potent CXCR4 Antagonists Containing Amidine Type Peptide Bond Isosteres
  117. HTLV-1 bZIP Factor Induces T-Cell Lymphoma and Systemic Inflammation In Vivo
  118. ATF3, an HTLV-1 bZip factor binding protein, promotes proliferation of adult T-cell leukemia cells
  119. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy
  120. Revisiting Human IL-12Rβ1 Deficiency
  121. Resistance Profiles of Novel Electrostatically Constrained HIV-1 Fusion Inhibitors
  122. HTLV-1 bZIP factor gene: Its roles in HTLV-1 pathogenesis
  123. Rev-derived peptides inhibit HIV-1 replication by antagonism of Rev and a co-receptor, CXCR4
  124. Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat
  125. APOBEC3G Generates Nonsense Mutations in Human T-Cell Leukemia Virus Type 1 Proviral Genomes In Vivo
  126. Binding of anionic porphyrins with V3 Loop fragments of HIV-1 envelope
  127. Affinity selection and sequence-activity relationships of HIV-1 membrane fusion inhibitors directed at the drug-resistant variants
  128. Synthesis and biological evaluation of selective CXCR4 antagonists containing alkene dipeptide isosteres
  129. Multi-Step Aberrant CpG Island Hyper-Methylation Is Associated with the Progression of Adult T–Cell Leukemia/Lymphoma
  130. Bioorganic synthesis of a recombinant HIV-1 fusion inhibitor, SC35EK, with an N-terminal pyroglutamate capping group
  131. Bioorganic synthesis of end-capped anti-HIV peptides by simultaneous cyanocysteine-mediated cleavages of recombinant proteins
  132. Mechanism of Inhibition of HIV-1 Reverse Transcriptase by 4′-Ethynyl-2-fluoro-2′-deoxyadenosine Triphosphate, a Translocation-defective Reverse Transcriptase Inhibitor
  133. X-ray Crystallographic Study of an HIV-1 Fusion Inhibitor with the gp41 S138A Substitution
  134. The HBZ gene, a key player in HTLV-1 pathogenesis
  135. Design and synthesis of membrane fusion inhibitors against the feline immunodeficiency virus
  136. Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients
  137. HBZ is an immunogenic protein, but not a target antigen for human T-cell leukemia virus type 1-specific cytotoxic T lymphocytes
  138. Synonymous mutations in stem-loop III of Rev responsive elements enhance HIV-1 replication impaired by primary mutations for resistance to enfuvirtide
  139. Electrostatically constrained α-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide
  140. In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP)
  141. Human T-cell leukemia virus type 1 bZIP factor selectively suppresses the classical pathway of NF- B
  142. Peptide bond mimicry by (E)-alkene and (Z)-fluoroalkene peptide isosteres: synthesis and bioevaluation of α-helical anti-HIV peptide analogues
  143. Maximizing Functional Photoreceptor Differentiation from Adult Human Retinal Stem Cells
  144. DNA double strand break repair enzymes function at multiple steps in retroviral infection
  145. Development of a Novel Fusion Inhibitor against T-20-resistant HIV-1
  146. SC29EK, a Peptide Fusion Inhibitor with Enhanced α-Helicity, Inhibits Replication of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide
  147. Design of Peptide-based Inhibitors for Human Immunodeficiency Virus Type 1 Strains Resistant to T-20
  148. SKI and MEL1 Cooperate to Inhibit Transforming Growth Factor-β Signal in Gastric Cancer Cells
  149. Roles for MicroRNAs, miR-93 and miR-130b, and Tumor Protein 53–Induced Nuclear Protein 1 Tumor Suppressor in Cell Growth Dysregulation by Human T-Cell Lymphotrophic Virus 1
  150. Identification of minimal sequence for HIV-1 fusion inhibitors
  151. Novel screening systems for HIV-1 fusion mediated by two extra-virion heptad repeats of gp41
  152. Transcriptional Control of Spliced and Unspliced Human T-Cell Leukemia Virus Type 1 bZIP Factor (HBZ) Gene
  153. A Potential Link between Alternative Splicing of theNBS1Gene and DNA Damage/Environmental Stress
  154. Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach
  155. Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-Intensity Conditioning for Adult T Cell Leukemia/Lymphoma: Impact of Antithymocyte Globulin on Clinical Outcome
  156. Synthesis and Application of Fluorescein- and Biotin-Labeled Molecular Probes for the Chemokine Receptor CXCR4
  157. Design of a Novel HIV-1 Fusion Inhibitor That Displays a Minimal Interface for Binding Affinity
  158. Amino Acid Mutation N348I in the Connection Subdomain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Multiclass Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors
  159. 2′-Deoxy-4′-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants
  160. Dual-Reporter Phenotypic Assay for Human Immunodeficiency Viruses
  161. 2′-Deoxy-4′-C-Ethynyl-2-Fluoroadenosine: A Nucleoside Reverse Transcriptase Inhibitor with Highly Potent Activity Against Wide Spectrum of HIV-1 Strains, Favorable Toxic Profiles, and Stability in Plasma
  162. Meeting Report on the 13th International Conference on Human Retrovirology: Human T-Cell Leukemia Virus Research 30 Years after Adult T-Cell Leukemia
  163. Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137)
  164. Heptad Repeat-Derived Peptides Block Protease-Mediated Direct Entry from the Cell Surface of Severe Acute Respiratory Syndrome Coronavirus but Not Entry via the Endosomal Pathway
  165. GANP suppresses DNA recombination, measured by direct-repeat ?-galactosidase gene construct, but does not suppress the type of recombination applying to immunoglobulin genes in mammalian cells
  166. Cooperation of NF-κB2/p100 Activation and the PDZ Domain Binding Motif Signal in Human T-Cell Leukemia Virus Type 1 (HTLV-1) Tax1 but Not HTLV-2 Tax2 Is Crucial for Interleukin-2-Independent Growth Transformation of a T-Cell Line
  167. Implication of the HTLV-I bZIP Factor Gene in the Leukemogenesis of Adult T-Cell Leukemia
  168. Activity against Human Immunodeficiency Virus Type 1, Intracellular Metabolism, and Effects on Human DNA Polymerases of 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine
  169. Development of adult T-cell leukemia in donor-derived human T-cell leukemia virus type I-infected T cells after allogeneic bone marrow transplantation
  170. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation
  171. Preferential Selection of Human T-Cell Leukemia Virus Type 1 Provirus Lacking the 5′ Long Terminal Repeat during Oncogenesis
  172. Phenotypic and Genotypic Comparisons of Human T-Cell Leukemia Virus Type 1 Reverse Transcriptases from Infected T-Cell Lines and Patient Samples
  173. Leukaemogenic mechanism of human T-cell leukaemia virus type I
  174. Chromosomal abnormalities in non-hodgkin lymphoma with peripheral t-cell type: Effect of HTLV-I infection
  175. De Novo Human T-Cell Leukemia Virus Type 1 Infection of Human Lymphocytes in NOD-SCID, Common γ-Chain Knockout Mice
  176. EGFRMutations in Small-Cell Lung Cancers in Patients Who Have Never Smoked
  177. Correction for Satou et al., HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells
  178. Donor-Derived T-Cell Leukemia after Bone Marrow Transplantation
  179. Ars Insulator Identified in Sea Urchin Possesses an Activity to Ensure the Transgene Expression in Mouse Cells
  180. Sea Urchin Arylsulfatase Insulator Exerts its Anti-silencing Effect without Interacting with the Nuclear Matrix
  181. Novel HIV-1 Integrase Inhibitors Derived from Quinolone Antibiotics
  182. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells
  183. Non-Hodgkin's Lymphomas of Childhood
  184. Loss of interleukin-2-dependency in HTLV-I-infected T cells on gene silencing of thioredoxin-binding protein-2
  185. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy
  186. Halogenated Thymidine Analogues Restore the Expression of Silenced Genes without Demethylation
  187. Human T-Cell Leukemia Virus Type I at Age 25: A Progress Report: Figure 1.
  188. Preferential selection of human T-cell leukemia virus type I provirus integration sites in leukemic versus carrier states
  189. Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Synthesis and structure–activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives
  190. Mutations Conferring Resistance to Human Immunodeficiency Virus Type 1 Fusion Inhibitors Are Restricted by gp41 and Rev-Responsive Element Functions
  191. RNase S complex bearing arginine-rich peptide and anti-HIV activity
  192. Design, Efficient Synthesis, and Anti‐HIV Activity of 4′‐C‐Cyano‐ and 4′‐C‐Ethynyl‐2′‐deoxy Purine Nucleosides
  193. Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Design and synthesis of thiazolidenebenzenesulfonamides
  194. Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naïve patients
  195. Identification of Aberrantly Methylated Genes in Association with Adult T-Cell Leukemia
  196. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro
  197. Role of HTLV-1 proviral DNA load and clonality in the development of adult T-cell leukemia/lymphoma in asymptomatic carriers
  198. Aberrant expression of the MEL1S gene identified in association with hypomethylation in adult T-cell leukemia cells
  199. Sea urchin insulator protects lentiviral vector from silencing by maintaining active chromatin structure
  200. Genetic and epigenetic inactivation oftax gene in adult T-cell leukemia cells
  201. Synthesis of 4′-C-Ethynyl and 4′-C-Cyano Purine Nucleosides from Natural Nucleosides and Their Anti-HIV Activity
  202. Human T-cell leukemia virus type I and adult T-cell leukemia
  203. Influence of cytokine and mannose binding protein gene polymorphisms on human t-cell leukemia virus type i (hTLV-i) provirus load in HTLV-I asymptomatic carriers
  204. Association between interleukin-6 gene polymorphism and human T-Cell leukemia virus type I associated myelopathy
  205. Central nervous system lesions in adult T-cell leukaemia: MRI and pathology
  206. Involvement of IL-2/IL-2R system activation by parasite antigen in polyclonal expansion of CD4+25+ HTLV-1-infected T-cells in human carriers of both HTLV-1 and S. stercoralis
  207. Genetic Evidence of Transmission of Human T Cell Lymphotropic Virus Type 1 between Spouses
  208. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappa B ligand on adult T-cell leukemia cells
  209. Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140
  210. Synthetic peptide-based electrochemiluminescence immunoassay for anti-Borna disease virus p40 and p24 antibodies in rat and horse serum
  211. Impaired production of naive T lymphocytes in human T-cell leukemia virus type I-infected individuals: its implications in the immunodeficient state
  212. 4′-Ethynyl Nucleoside Analogs: Potent Inhibitors of Multidrug-Resistant Human Immunodeficiency Virus Variants In Vitro
  213. Missense mutation of the interleukin-12 receptor beta1 chain-encoding gene is associated with impaired immunity against Mycobacterium avium complex infection
  214. Sequential Change of Virus Markers in Seroconverters with Community‐Acquired Infection of Human T Lymphotropic Virus Type I
  215. The possible involvement of CXCR4 in the inhibition of HIV-1 infection mediated by DP178/gp41
  216. Tumor necrosis factor, tumor necrosis factor receptors type 1 and 2, lymphotoxin-α, and HLA-DRB1 gene polymorphisms in human T-Cell lymphotropic virus type I associated myelopathy
  217. Syntheses of 4‘-C-Ethynyl-β-d-arabino-and 4‘-C-Ethynyl-2‘-deoxy-β-d-ribo-pentofuranosylpyrimidines and -purines and Evaluation of Their Anti-HIV Activity
  218. Identification of Human Autoantibodies to the Transcriptional Repressor ZF5
  219. Polymorphism of the 5′‐Flanking Region of the Tumor Necrosis Factor (TNF)–α Gene and Susceptibility to Human T‐Cell Lymphotropic Virus Type I (HTLV‐I) Uveitis
  220. Rapid quantification of HTLV-I provirus load: Detection of monoclonal proliferation of HTLV-I-infected cells among blood donors
  221. Random integration of HTLV-I provirus; increasing chromosomal instability
  222. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins
  223. DNA Diagnosis of HTLV-I
  224. The 3′ enhancer region determines the B/T specificity and pro-B/pre-B specificity of immunoglobulin Vκ-Jκ joining
  225. Deregulated c-fos Modulates B Cell Responses to Switch Mediators
  226. Immunoglobulin switch circular DNA in the mouse infected with Nippostrongylus brasiliensis: evidence for successive class switching from mu to epsilon via gamma 1.
  227. A B-CELL LINE HAVING CHROMOSOME 14 ABERRATION AT BREAK BAND qll DERIVED FROM AN ADULT T-CELL LEUKEMIA PATIENT
  228. Expression of the HT462 antigen on fresh leukemic T cells and on cells of HTLV-I infected lines
  229. T Cell γ Chain Gene Rearrangement without T Cell Receptor β Chain Gene Rearrangement in Two Cases of Non-Hodgkin’s Lymphoma
  230. Analysis of anti-HTLV-I antibody by strip radioimmunoassay—comparison with indirect immunofluorescence assay, enzyme-linked immunosorbent assay and membrane immunofluorescence assay
  231. Expression of tac antigen on human immature B-cell lineage leukemic cells
  232. HTLV-III Infection and Epitope Recognition by OKT4 Monoclonal Antibody